BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 30006143)

  • 1. Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines.
    Wang C; Li S; Meng Q; Sun X; Li H; Shu X; Sun H; Liu K; Liu Z; Ma X
    Bioorg Med Chem; 2018 Aug; 26(14):4179-4186. PubMed ID: 30006143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of novel 1-substituted 3-(3-phenoxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.
    Zheng N; Hao Q; Lin K; Pan J; Li Y; Zhou W
    Bioorg Med Chem Lett; 2019 Jan; 29(2):225-229. PubMed ID: 30522954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma.
    Ran F; Liu Y; Chen X; Zhuo H; Xu C; Li Y; Duan X; Zhao G
    Bioorg Chem; 2021 Jul; 112():104968. PubMed ID: 34000704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
    Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J
    Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines.
    Ge Y; Yang H; Wang C; Meng Q; Li L; Sun H; Zhen Y; Liu K; Li Y; Ma X
    Bioorg Med Chem; 2017 Jan; 25(2):765-772. PubMed ID: 27956037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma.
    Ge Y; Wang C; Song S; Huang J; Liu Z; Li Y; Meng Q; Zhang J; Yao J; Liu K; Ma X; Sun X
    Eur J Med Chem; 2018 Jan; 143():1847-1857. PubMed ID: 29146136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma.
    Ran F; Liu Y; Yu S; Guo K; Tang W; Chen X; Zhao G
    Bioorg Chem; 2020 Jan; 94():103367. PubMed ID: 31685258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
    Guo X; Yang D; Fan Z; Zhang N; Zhao B; Huang C; Wang F; Ma R; Meng M; Deng Y
    Eur J Med Chem; 2019 Sep; 178():767-781. PubMed ID: 31234030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological activity of imidazole group-substituted arylaminopyrimidines (IAAPs) as potent BTK inhibitors against B-cell lymphoma and AML.
    Li S; Wu B; Zheng X; Wang C; Zhao J; Sun H; Sun X; Tang Z; Yuan H; Chen L; Ma X
    Bioorg Chem; 2021 Jan; 106():104385. PubMed ID: 33272709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
    Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X
    Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel BTK PROTACs for B-Cell lymphomas.
    Zhao Y; Shu Y; Lin J; Chen Z; Xie Q; Bao Y; Lu L; Sun N; Wang Y
    Eur J Med Chem; 2021 Dec; 225():113820. PubMed ID: 34509879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Bruton's tyrosine kinase inhibitors.
    Diao Y; Fang X; Song P; Lai M; Tong L; Hao Y; Dou D; Liu Y; Ding J; Zhao Z; Xie H; Li H
    Bioorg Med Chem; 2019 Aug; 27(15):3390-3395. PubMed ID: 31221612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of pyrazolopyrimidine derivatives as potent BTK inhibitors with effective anticancer activity in MCL.
    Ran F; Liu Y; Liu M; Zhang D; Wang P; Dong J; Tang W; Zhao G
    Bioorg Chem; 2019 Aug; 89():102943. PubMed ID: 31031018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
    Maher M; Kassab AE; Zaher AF; Mahmoud Z
    Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of pyrido[3,4-b]indol-1-one derivatives as novel non-covalent Bruton's tyrosine kinase (BTK) inhibitors.
    Dou D; Sha W; Diao Y; Su R; Qiao Y; Yu Z; Zhao Z; Li H; Chen Z; Xu Y
    Bioorg Chem; 2022 Feb; 119():105541. PubMed ID: 34910982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.
    Zhang C; Pei H; He J; Zhu J; Li W; Niu T; Xiang M; Chen L
    Eur J Med Chem; 2019 May; 169():121-143. PubMed ID: 30875504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines.
    Zhao D; Huang S; Qu M; Wang C; Liu Z; Li Z; Peng J; Liu K; Li Y; Ma X; Shu X
    Eur J Med Chem; 2017 Jan; 126():444-455. PubMed ID: 27912175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK3 inhibitors based on thieno[3,2-d]pyrimidine scaffold: design, synthesis and bioactivity evaluation for the treatment of B-cell lymphoma.
    Chi F; Chen L; Wang C; Li L; Sun X; Xu Y; Ma T; Liu K; Ma X; Shu X
    Bioorg Chem; 2020 Jan; 95():103542. PubMed ID: 31918398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.
    Ding N; Li X; Shi Y; Ping L; Wu L; Fu K; Feng L; Zheng X; Song Y; Pan Z; Zhu J
    Oncotarget; 2015 Jun; 6(17):15122-36. PubMed ID: 25944695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
    Teng Y; Lu X; Xiao M; Li Z; Zou Y; Ren S; Cheng Y; Luo G; Xiang H
    Eur J Med Chem; 2020 Aug; 199():112339. PubMed ID: 32402933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.